Ormeloxifene A Selective Estrogen Receptor Modulator , For Treatment Of Dysfunctional Menorrhagia Biswas

OBJECTIVE To evaluate the efficacy of Ormeloxifene for dysfunctional menorrhagia (DUB). METHODS Eighty five women aged 30 to 51 years who attended the outpatient gynecology department with complaint of heavy menstrual flow were recruited for the study. Ormeloxifene (60 mg)was given orally twice a week for first 12 weeks and then once a week for up to next 12 weeks. Menstrual blood loss measurements using pictorial blood loss assessment chart (PBAC), blood hemoglobin (gm/ dl) levels and endometrial thickness were the main measurements to evaluate the efficacy of therapy. Statistical analysis was done using a paired 't' test and ,z' test. RESULTS The median difference between pretreatment and post-treatment PBAC score of 97.2 was statistically significant (P<O.OOl). The difference in mean hemoglobin concentration of 1.31 gm/ dl between pretreatment and post-treatment levels was also statistically significant (P<O.OOl, 95% CI= 0.389 to 2.23). Seventy four out of 85 subjects (87.05%) showed a reduction in endometrial thickness as assessed by transvaginal sonography(TVS). Only se out of 85 (8.2%) women needed hysterectomy. CONCLUSION Because of convenient dosage schedule and higher cost-benefit ratio, ormeloxifene is an effective drug therapy in dysfunctional menorrhagia.